Abstract No. 2622: PERIO-02: Phase 1b Pressure Enabled Regional Immuno-oncology Trial of nelitolimod (SD-101), a Class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma
… Clinical Efficacy of Pressure-Enabled Transarterial Embolization of Hypovascular, Treatment-Refractory Metastases.
… The PERIO-03 Trial: Technical Feasibility and Safety of a Novel Pancreatic Retrograde Venous Immunotherapy Infusion Intervention for Locally Advanced Pancreatic Ductal Adenocarcinoma.
… Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases
… Clinical Activity of SD-101 with Immune Checkpoint Inhibition (ICI) in Metastatic Uveal Melanoma Liver Metastasis (MUM-LM) from the PERIO-01 Phase 1 Trial
… Checkpoint Inhibitor Administered Either Systemically or Subcutaneously Enhances the Anti-Tumor Immunity of SD-101 Delivered by Pressure-Enabled Drug Delivery (PEDD™) Device in Treating Liver Metastasis (LM)
… PERIO-03: Pressure-Enabled Intrapancreatic Delivery of SD-101 with Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma – Initial Safety and Feasibility Experience
… PERIO-01: Initial Safety Experience and Immunologic Effects of a Class C TLR9 Agonist Using Pressure-Enabled Drug Delivery (PEDD™) in a Phase 1 Trial of Hepatic Arterial Infusion of SD-101 +/- Checkpoint Inhibition in Metastatic Uveal Melanoma
… Enhanced Delivery of Anti PD-1 Antibody to Liver Tumors in Oncopig Using Pressure-Enabled Drug Delivery (PEDD™) Versus Systemic Delivery
… Pancreatic Venous Anatomy for Trans-Portal Treatment of Pancreatic Cancers using Pressure-Enabled Drug Delivery (PEDD™)
…